Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10241 plus Almonertinib in EGFRm+ MET-positive NSCLC
NCT05430386Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalmelitinib in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at Day 28 and Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
dalmelitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05430386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430386.